selected publications
-
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 379 -
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 258 -
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 379 -
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 691 - Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer. Cancer. 2018 Editorial Article GET IT
-
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 1109 -
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 351 -
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Cancer.
2017
Academic Article
GET IT
Times cited: 29 -
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
PloS one.
2017
Academic Article
GET IT
Times cited: 58 -
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.
OncoTargets and therapy.
2017
Information Resource
GET IT
Times cited: 54 -
Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.
Current oncology reports.
2017
Information Resource
GET IT
Times cited: 36 -
Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Hematology/oncology clinics of North America.
2017
Information Resource
GET IT
Times cited: 46